MedTrace Logo

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

NCT05415345 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2022-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the immunogenicity and safety of co-immunization with recombinant human papillomavirus bivalent (Types 16,18) vaccine (Escherichia coli) and Hepatitis E vaccine (Escherichia coli)

Conditions

  • Human Papilloma Virus Infection Type 16
  • Human Papilloma Virus Infection Type 18
  • Hepatitis E Virus Infection

Interventions

BIOLOGICAL

Cecolin

Bivalent HPV Vaccine

BIOLOGICAL

Hecolin

Hepatitis E vaccine

Sponsors & Collaborators

  • Zhejiang Provincial Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • Xiamen Innovax Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Zhenggang Jiang · Zhejiang Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2022-11-30
Completion
2023-06-10

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415345 on ClinicalTrials.gov